SEARCH

SEARCH BY CITATION

References

  • 1
    Browning JD, Szczepaniak LS, Dobbis R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387-1395.
  • 2
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
  • 3
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
  • 4
    Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-678.
  • 5
    Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletionof hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004; 37: 1499-1507.
  • 6
    Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. HEPATOLOGY 2004; 40: 185-194.
  • 7
    Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. HEPATOLOGY 2008; 47: 1495-1503.
  • 8
    Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99: 1497-1502.
  • 9
    Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005; 5: 35.
  • 10
    Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. HEPATOLOGY 2009; 50: 1827-1838.
  • 11
    Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, et al. Mass spectrometric profiling of oxidized lipid products in human alcoholic liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 51: 3046-3054.
  • 12
    Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. HEPATOLOGY 2011; 54: 1610-1619.
  • 13
    Zein CO, Lopez R, Yerian LM, Anderson KA, McCullough AJ, Rinella ME. Pentoxifylline improves non-invasive serum markers of fibrosis: combined results from 2 randomized, placebo-controlled trials. Presentation at Digestive Disease Week, San Diego, CA, May 2012.
  • 14
    Ward A, Clissold S. Pentoxifylline. Review of its pharmacodynamic and pharmacokinetic properties. Drugs 1987; 34: 50-97.
  • 15
    Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Int J Immunopharmacol 1996; 18: 739-748.
  • 16
    Zhang M, Xu UJ, Saini HK, Turan B, Liu PP, Dhalla NS. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 2005; 289: H832-H839.
  • 17
    Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198.
  • 18
    El-lakkany N, El-Din SS, Ebeid F. The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental schistosomiasis mansoni. Exp Parasitol 2011; 129: 152-157.
  • 19
    Vircheva S, Alexandrova A, Georgieva A, Mateeva P, Zamfirova R, Kubera M, et al. In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation. Cell Biochem Funct 2010; 28: 668-672.
  • 20
    Kozaki K, Egawa H, Bermudez L, Keefe EB, So SK, Esquivel CO. Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation. HEPATOLOGY 1995; 21: 1079-1082.
  • 21
    Koppe SW, Sahai A, Malladi P, Whittington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004; 41: 592-598.
  • 22
    Freitas JP, Filipe PM. Pentoxifylline: a hydroxyl radical scavenger. Biol Trace Elem Res 1995; 47: 307-311.
  • 23
    Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 2001; 288: 1212-1217.
  • 24
    Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192: 313-322.
  • 25
    Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline and oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double blind placebo-controlled trial. Biomed Pharmacother 2005; 59: 302-306.
  • 26
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
  • 27
    Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG, et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006; 41: 1678-1683.
  • 28
    Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: E667-E677.
  • 29
    Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990; 71: 1508-1518.
  • 30
    Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003; 5: 1003-1015.
  • 31
    Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79: 790-800.
  • 32
    Yoshida Y, Niki E. Bio-markers of lipid peroxidation in vivo: hydroxyoctadecadienoic acid and hydroxycholesterol. BioFactors 2006; 27: 195-202.
  • 33
    Niki E, Yoshida Y. Biomarkers of oxidative stress: measurement, validation and application. Proc J Med Invest 2005; 52( Suppl): 228-230.
  • 34
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-845.
  • 35
    Cortez-Pinto H, de Moura MC, Day CP. Nonalcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006; 44: 197-208.
  • 36
    Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat storing cells. Biochem Biophys Res Commun 1993; 194: 1044-1050.
  • 37
    Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192: 313-322.
  • 38
    Radfar M, Larijani B, Hadjibbaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized controlled clinical trial. Biomed Pharmacother 2005; 302-306.
  • 39
    Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50: 241-247.
  • 40
    Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of nonalcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-286.
  • 41
    Utzschneider KM, Khan SE. Insulin action and beta-cell function: role in metabolic regulation. In: Eckel RH, editor. metabolic risk for cardiovascular disease, 1st ed. 2011 American Heart Association. London: Blackwell. p 1-17.
  • 42
    Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
  • 43
    Cnop W, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of B-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682.
  • 44
    Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes. Diabetes 2006; 55: 1074-1079.
  • 45
    Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642.